| Background：Bronchial asthma is a common serious global health problem. Thischronic airway disease can be accumulated in different countries, different regionsand races, different age groups, severe cases can cause death. Pathogenesis ofbronchial asthma complicated, There is no cure. Worldwide burden of disease relatedto both its heavy, effective asthma control depends on the concerted efforts of bothdoctors and patients. Inhalation treatment of bronchial asthma is the world’s Initiativefor Asthma (GINA) in the treatment of choice, wide range of clinical health workersattached to it. The role of inhalation therapy become the preferred treatment ofbronchial asthma, thank to rapidly and side effects is small, easy to use, lessmedication and other advantages.In the late20th century, people began to study50used inhaled corticosteroids (ICS).Budesonide is one of the anti-inflammatoryinhaled corticosteroids. Glucocorticoid receptor affinity higher. By inhibiting the aggregation and activation of inflammatorycells, epithelial cell proliferation and damage and basement membrane thickening,reduce the vascular permeability and angiogenesis, etc.And reversal of airway reactivity and ease the speed of hair caused by delayedtypehyper sensitivity airway inflammation and bronchial obstruction; Inhibit therelease of inflammatory mediators and factor-mediated immune response, To achievethe anti-allergic inflammation and anti-inflammatory effect. in the clinical applicationof ICS in moderate persistent asthma program for a good efficacy in patients. can beeffective in reducing asthma symptoms, improve quality of life, improve lungfunction, decrease airway hyperres ponsiveness, airway inflammation control andreduce asthma Reduce seizure frequency and severity of attacks, reduce mortality,improve patient compliance. Rapid onset, significantly improved lung function, moreeffective than single skin with high doses of inhaled steroid, and significantly reducethe hormone dosage, symptoms worsen rate decreased. In clinical applications, a morepromising future.Objective: To investigate the budesonide treatment of bronchial asthma patients withinhaled CD4~+CD25~+Treg and pulmonary function, and to further explore the newways of trea.Methods:48cases of eligible patients with acute exacerbation of bronchialasthmawere randomly divided into two groups, control group and treatment group of 24cases.Control group of antibiotics and other conventional treatment Doxofylline;treatment group was given conventional therapy inhalation budesonide2times.Regimens for2weeks. Measured before and after treatment in patients withCD4~+CD25~+Teeg and lung function, compared two groups of patients improved aftertreatment with or without significant difference between the indicators to evaluatetwomethods treatment of bronchial asthma.Results:1, acute exacerbation of bronchial asthma patients in vivo CD4~+CD25~+Treglevels were significantly higher in the treatment group and control group, these factorsdecreased the water (P <0.05), the treatment group decreased more significantly thanthe control group, the difference was significant Significance (P <0.05).4, acuteexacerbation of bronchial asthma patients showed obstructive ventilatory dysfunction,it is PEF, FEV1/FVC%were reduced. After the treatment, PEF, FEV1/FVC%weresignificantly increased (P <0.01). The treatment group increased more significantlythan the control group (P <0.01).Conclusion1，Inhal bdesonide therapy CD4~+CD25~+Treg were higher than thosebefore the fall (P <0.05),2, acute attack of bronchial asthma lung function wasobstructive ventilatory dysfunction, and budesonide inhalation therapy combined caneffectively improve lung function.3, Inhalation of budesonid suspension aerosol in treatment of patients with bronchial asthma is more effectiveand it may be recommended for further clinical application．... |
PDF Full Text Request